Dr. Hoos Explains the Future of Immunotherapy

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, describes that immunotherapy is still an emerging field, even though it has been around for a long time. He believes acceptance of immunotherapy is increasing in the oncology community and that immunotherapy will become one of the key treatment modalities in the coming years.